Skip to main content
COVID-19 Update: Many people are being asked to stay home to slow the spread of COVID-19... Many people are being asked to stay home to slow the spread of COVID-19. INBRIJA® (levodopa inhalation powder) continues to be delivered directly to patients' residences, so you can still receive your medication even if you are homebound for a prolonged period of time...
Patient Information For US Residents Only

Real INBRIJA® Stories

Get a glimpse into the lives of real people living with Parkinson's. See how they're using INBRIJA to get back to the moment when their Parkinson's symptoms start to return. Scroll down to meet them.

Go to Bettina's story Go to Bettina's story Go to Bob's story Go to Bob's story Go to Jimmy's story Go to Jimmy's story Go to John's story Go to John's story Go to Stephanie's story Go to Stephanie's story

Meet Bettina

A marketing professional, mom to her dog Blanche, and an airplane enthusiast who was diagnosed with Parkinson's in 2007 at 34 years old.

Watch Bettina's Story

Meet John

A husband, motivational speaker, and author who was diagnosed with Parkinson's in 2003 at 41 years old.

Watch John's Story

Meet Stephanie

A daughter of a Person with Parkinson's, who herself was diagnosed in 2009 at the age of 54 and became a leader and strong advocate in the Parkinson's community.

Watch Stephanie's Story

Meet Bob

A father, husband, and former business owner who was first diagnosed with Parkinson's in 2006, when he was 57 years old.

Watch Bob's Story

Meet Jimmy

A proud grandpa, husband, and retired Army National Guard helicopter pilot who was diagnosed with Parkinson's in 2007 when he was 39 years old.

Educational Programs

Interact with real people taking INBRIJA and learn more at our FREE educational programs. These programs are open to People with Parkinson's and their Care Partners.

Get started using the symptom checklist

These real INBRIJA patients didn't sit around and wait for their Parkinson's symptoms to continue disrupting their daily life—and you may not have to either. Use the interactive symptom checklist to see if you are experiencing a return of symptoms.

Go to interactive symptom checklist

Talk with your doctor

Need help preparing to make the most of your next doctor visit? The Doctor Discussion Guide is a great way to get started.

Download Doctor Discussion Guide

Have questions?

Contact us at 1‑833‑INBRIJA

INBRIJA® Indication

Treats OFF periods in adults taking carbidopa/levodopa (CD/LD). INBRIJA doesn’t replace CD/LD.

Important Safety Information

Don’t use if you have taken a nonselective monoamine oxidase inhibitor (eg, phenelzine, tranylcypromine) within the last 2 weeks.


INBRIJA is a prescription medicine used when needed for OFF episodes in adults with Parkinson’s treated with regular carbidopa/levodopa medicine. INBRIJA does not replace regular carbidopa/levodopa medicine.

Important Safety Information

Do not use INBRIJA if you take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last 2 weeks.

Before using INBRIJA, tell your healthcare provider about your medical conditions, including:

  • asthma, chronic obstructive pulmonary disease (COPD), or any chronic lung disease
  • daytime sleepiness, sleep disorders, sleepiness/drowsiness without warning, or use of medicine that increases sleepiness, including antidepressants or antipsychotics
  • dizziness, nausea, sweating, or fainting when standing up
  • abnormal movement (dyskinesia)
  • mental health problems such as hallucinations or psychosis
  • uncontrollable urges like gambling, sexual urges, spending money, or binge eating
  • glaucoma
  • pregnancy or plans to become pregnant. It is unknown if INBRIJA will harm an unborn baby.
  • breastfeeding or plans to breastfeed. Levodopa can pass into breastmilk and it is unknown if it can harm the baby.

Tell your healthcare provider if you take:

  • MAO-B inhibitors
  • dopamine (D2) antagonists (including phenothiazines, butyrophenones, risperidone, metoclopramide)
  • isoniazid
  • iron salts or multivitamins that contain iron salts

Do not drive, operate machinery, or do other activities until you know how INBRIJA affects you. Sleepiness and falling asleep suddenly can happen as late as a year after treatment is started.

Tell your healthcare provider if you experience the following side effects:

  • falling asleep during normal daily activities with or without warning. If you become drowsy, do not drive or do activities where you need to be alert. Chances of falling asleep during normal activities increases if you take medicine that cause sleepiness.
  • withdrawal-emergent hyperpyrexia and confusion (fever, stiff muscles, or changes in breathing and heartbeat) if you suddenly stop using INBRIJA or carbidopa/levodopa, or suddenly lower your dose of carbidopa/levodopa.
  • low blood pressure when standing up (that may be with dizziness, fainting, nausea, and sweating). Get up slowly after sitting/lying down.
  • hallucinations and other psychosis – INBRIJA may cause or worsen seeing/hearing/believing things that are not real; confusion, disorientation, or disorganized thinking; trouble sleeping; dreaming a lot; being overly suspicious or feeling people want to harm you; acting aggressive; and feeling agitated/restless.
  • unusual uncontrollable urges such as gambling, binge eating, shopping, and sexual urges has occurred in some people using medicine like INBRIJA.
  • uncontrolled, sudden body movements (dyskinesia) may be caused or worsened by INBRIJA. INBRIJA may need to be stopped or other Parkinson’s medicines may need to be changed.
  • bronchospasm – people with asthma, COPD, or other lung diseases may wheeze or have difficulty breathing after inhaling INBRIJA. If this occurs, stop taking INBRIJA and seek immediate medical attention.
  • increased eye pressure in patients with glaucoma. Your healthcare provider should monitor this.
  • changes in certain lab values including liver tests

The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Do not orally inhale more than 1 dose (2 capsules) for any OFF period. Do not take more than 5 doses (10 capsules) in a day.

Please see the Patient Information Leaflet.